Health Canada

Brain Canada Celebrates Brain Health Awareness Month with Boost your Brain Awareness Campaign

Retrieved on: 
Monday, March 11, 2024

MONTREAL, March 11, 2024 (GLOBE NEWSWIRE) --  Brain Canada is marking this year’s Brain Health Awareness Month by launching the Boost your Brain Awareness campaign to draw attention to how the body’s most critical organ works in health and illness.

Key Points: 
  • Brain Canada marks 2024 Brain Health Awareness Month with a Boost your Brain Awareness Campaign to better understand our most critical organ in health and illness.
  • MONTREAL, March 11, 2024 (GLOBE NEWSWIRE) -- Brain Canada is marking this year’s Brain Health Awareness Month by launching the Boost your Brain Awareness campaign to draw attention to how the body’s most critical organ works in health and illness.
  • This month, Brain Canada will be highlighting different ways to boost our brain awareness.
  • “Brain Health Awareness Month is an opportunity to remind people in Canada of the critical role research plays in maintaining and improving our collective brain health,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

Empowering Women in the Natural Health Product Industry on International Women’s Day

Retrieved on: 
Friday, March 8, 2024

Health Canada’s proposed regulations will decimate the NHP industry, disproportionately impacting women and women-led businesses.

Key Points: 
  • Health Canada’s proposed regulations will decimate the NHP industry, disproportionately impacting women and women-led businesses.
  • This International Women’s Day, the Canadian Health Food Association (CHFA) is calling on the federal government to press pause.
  • “Many of these businesses will be forced to close.”
    It's a well-known fact that women have been historically neglected in health research, and Health Canada’s latest regulatory reform on NHPs is no exception.
  • Women are much more likely to purchase NHPs, but Health Canada’s changes will take safe, compliant Canadian products off Canadian shelves.

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
Thursday, March 7, 2024

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

Optimi Announces Closing of First Tranche of Non-Brokered Private Placement

Retrieved on: 
Wednesday, February 28, 2024

The Company intends to use the net proceeds from the Offering to obtain its Drug Establishment License, facilitate commercialization, and for general working capital.

Key Points: 
  • The Company intends to use the net proceeds from the Offering to obtain its Drug Establishment License, facilitate commercialization, and for general working capital.
  • JJ Wilson and Dane Stevens, co-founders of Optimi, emphasize, “We are fully dedicated to Optimi's mission of becoming the leading end-to-end supplier of GMP psychedelics.
  • In addition to the financing, the Company also announces that specific founders have agreed to a one-year voluntary lock-up period for their founder shares.
  • This additional commitment, along with the founders' participation in the financing, emphasizes their dedication to commercializing the business and establishing sustainable markets for its products.

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.

Key Points: 
  • The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.
  • Total revenues for the quarter ended December 31, 2023 were $13.5 million compared to $3.0 million for the corresponding period in 2022.
  • Net cash used in operating activities was $56.2 during the fourth quarter and $247.1 million during the full year 2023.
  • Arcutis management will host a conference call and webcast today at 8:30 am ET to discuss the financial results for the quarter and year and provide a business update.

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

Retrieved on: 
Monday, February 26, 2024

Health Canada stated that a Request for Reconsideration can be filed within 30 days of receiving the NON/w.

Key Points: 
  • Health Canada stated that a Request for Reconsideration can be filed within 30 days of receiving the NON/w.
  • The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the original submission.
  • AB Science provided a methodologically justified new claim “patients with ALS prior to any loss of function”, where CAFS and Overall Survival (OS) are significantly improved.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.

Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

Retrieved on: 
Friday, February 23, 2024

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.

Key Points: 
  • EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.
  • In addition to the proposed Arrangement, the Company continues to execute on progress across its ongoing development projects, as detailed below.
  • “We continue to make promising progress across all areas of our business.
  • Given the recent developments, we anticipate that all key success factors will align to expand our business model.

Drug insurance: A single-payer pharmacare program would jeopardize coverage quality for 21 million Canadians

Retrieved on: 
Thursday, February 22, 2024

“All across the country, private drug insurance plans cover more treatments than governmental plans,” explains Emmanuelle B. Faubert, economist at the MEI and author of the study.

Key Points: 
  • “All across the country, private drug insurance plans cover more treatments than governmental plans,” explains Emmanuelle B. Faubert, economist at the MEI and author of the study.
  • Nearly 25 million Canadians have private drug insurance coverage.
  • Between 2018 and 2021, private drug insurance plans covered 51 per cent more drugs on average than public plans.
  • The MEI study indicates that even if a public plan as generous as Quebec’s were extended across the country, 21.5 million Canadians would risk seeing the quality of their insurance coverage fall.

Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis

Retrieved on: 
Tuesday, February 20, 2024

Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass.

Key Points: 
  • Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass.
  • Health Canada approval based on robust Phase I and Phase III clinical studies.
  • BOUCHERVILLE, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti® (denosumab subcutaneous injection, reference medicine: Prolia*).
  • Jubbonti® is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass.

QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada

Retrieved on: 
Wednesday, March 6, 2024

QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.
  • The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor (“PLGF”) in maternal plasma specimens.
  • With the Triage PLGF test, clinicians can be positioned to better detect angiogenic imbalance and assess the risk for these complications.
  • The Triage PLGF test is available to customers in Canada for use with the Triage MeterPro instrument.